Home
|
News
|
Events
|
Contact Us
|
English
|
繁體中文
|
日本語
About Us
Product & Service
Facilities
Quality & Compliance
For Investors
Career
|
Company
|
Milestone
|
People
|
Mission Statement
|
Organization
|
Contact Us
|
|
Active Pharmaceutical Ingredients
|
Contract Development and Manufacturing Organization (CDMO)
|
Antibody Drug Conjugates (ADCs)
|
Injectable Manufacturing Services
|
|
Kilo Lab
|
Commercial Production
|
High Potency API (HPAPI)
|
Analytical instrument
|
|
DMFs & CEPs
|
Inspection
|
Certificates
|
SHE Policy
|
Intellectual Property
|
Award
|
|
Financials
|
Corporate Governance
|
Shareholder Services
|
CSR
|
FAQ
For Investors
Home
/
For Investors
Material Announcement
2022-08-11
公告本公司董事會通過111年度第二季合併財務報告
2022-08-10
本公司今日與重要子公司台新藥股份有限公司共同召開重大 訊息說明記者會之新聞稿內容
2022-08-10
本公司重要子公司台新藥股份有限公司APP13007第三期臨床 試驗CPN-302取得顯著有效的主要療效數據
2022-08-09
2022-08-08
公告本公司將與重要子公司台新藥股份有限公司共同召開記者會
Financials
合併季報表、公開資訊觀測站及股價資訊查詢
Corporate Governance
提供公司治理相關資訊
Shareholder Services
提供各項重要股東相關資訊
Corporate Social Responsibility
各種社會活動花絮,含新聞影像資源
FAQ
股票過戶機構、股務及投資人聯絡窗口、常見問答
Financials
Annual Reports
Monthly Revenue
Finacial Reports
Corporate Governance
Board of Directors
Major Policies
Intermal Audit
Major Resolutions
Shareholder Services
Stock Quotes & Dividend Data
Material Announcement
Shareholders' Meeting
Activities
CSR
Corporate Social Responsibility
Stakeholder Engagement
Public Welfare
FAQ
Common Share Transfer
Contacts
FAQ
Copyright ©2014 Formosa Laboratories, Inc. All Rights Reserved.
丙肝